<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We planned a multicenter randomized phase III study to evaluate the efficacy of appropriate dose of bevacizumab (5 or 10 mg/kg) with FOLFIRI in patients with advanced/<z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> who have failed prior bevacizumab plus <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based therapy </plain></SENT>
<SENT sid="1" pm="."><plain>The primary endpoint is progression-free survival </plain></SENT>
<SENT sid="2" pm="."><plain>The secondary endpoints are the toxicity, response rate, time to treatment failure, overall survival, overall survival from the start of the first-line treatment and second progression-free survival (time duration from the initiation of the first-line treatment until progression after the protocol treatment) </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 370 patients were considered to be appropriate for this trial </plain></SENT>
</text></document>